国产小分子抗癌药拿下重磅适应症

动脉网
Mar 05

近日,轩竹生物的吡洛西利片获NMPA批准新增适应症,联合芳香化酶抑制剂用于HR+/HER2-晚期乳腺癌初始内分泌治疗,成为国内首个且唯一覆盖该类乳腺癌全疗程的同类药物。此次获批基于BRIGHT-3研究,数据显示吡洛西利联合AI组中位无进展生存期未达,两年PFS率超60%,客观缓解率高达63.5%,疗效优异。吡洛西利是国内首个获批的CDK2/4/6抑制剂,可强效抑制肿瘤细胞增殖,降低血液学毒性,提升...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10